Skip to main content
Evan Wuthrick, MD, Radiation Oncology, Tampa, FL, H. Lee Moffitt Cancer Center and Research Institute

EvanJohnWuthrickMD

Radiation Oncology Tampa, FL

Gastrointestinal Cancer

Assistant Professor, Radiation Oncology, Ohio State University College of Medicine

Overview of Dr. Wuthrick

Dr. Evan Wuthrick is a radiation oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from Sidney Kimmel Medical College at Thomas Jefferson University and has been in practice 11 years. He is one of 60 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Radiation Oncology. He has more than 40 publications and over 500 citings.

Education & Training

  • Sidney Kimmel Medical College at Thomas Jefferson University/TJUH
    Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Radiation Oncology, 2007 - 2011
  • Albert Einstein Medical Center
    Albert Einstein Medical CenterInternship, Transitional Year, 2006 - 2007
  • Sidney Kimmel Medical College at Thomas Jefferson University
    Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 2006

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2017 - 2026
  • OH State Medical License
    OH State Medical License 2011 - 2017
  • PA State Medical License
    PA State Medical License 2006 - 2011
  • American Board of Radiology Radiation Oncology

Awards, Honors, & Recognition

  • Residency Program Director in Radiation Oncology
  • Vice Chair, Cancer Institutional Review Board
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Experience Counts with Radiation Therapy for Head and Neck Cancer, Study Shows
    Experience Counts with Radiation Therapy for Head and Neck Cancer, Study ShowsDecember 9th, 2014

Grant Support

  • A PHASE I TRIAL OF MEK INHIBITOR GSK1120212 (TRAMETINIB) IN COMBINATION WITH NEOADJUVANT 5-FLOUROURACIL CHEMORADIATION IN THE TREATMENT OF KRAS, BRAF, AND NRAS-MUTANT RECTAL CANCERS,National Comprehensive Cancer NetworkPresent

Hospital Affiliations